Skip to main content

BookStack

Search Shelves Books Log in

Details

Revision #1

Created 2 months ago by Omar Ayman

Updated 2 months ago by Omar Ayman

Actions

Revisions

Contained Web File.html
PDF File.pdf
Plain Text File.txt
Markdown File.md
Portable ZIP.zip

Page Navigation

Agranulocytosis

Book Navigation

Maudsley's guidelines
06 - Chapter 1 Schizophrenia and related psychoses
07 - Chapter 2 Bipolar disorder
08 - Chapter 3 Depression and anxiety disorders
09 - Chapter 4 Addictions and substance misuse
10 - Chapter 5 Prescribing in children and adolescents
11 - Chapter 6 Prescribing in older people
12 - Chapter 7 Prescribing in pregnancy and breastfeedi
13 - Chapter 8 Prescribing in hepatic and renal impairm
14 - Chapter 9 Drug treatment of other psychiatric cond
15 - Chapter 10 Drug treatment of psychiatric symptoms
16 - Chapter 11 Pharmacokinetics
17 - Chapter 12 Other substances
18 - Chapter 13 Psychotropic drugs in special condition
19 - Chapter 14 Prescribing psychotropics
20 - Chapter 15 Miscellany

Books

Maudsley's guidelines

06 - Chapter 1 Schizop...

246 - Agranulocytosis

Agranulocytosis

No comments to display

Back to top

01 - ANTIPSYCHOTIC DRUGS

02 - General introduction

03 - Classification of antipsychotics

04 - Choosing an antipsychotic

05 - Relative efficacy

06 - References

07 - General principles of prescribing

08 - Antipsychotics minimum effective doses

09 - References

10 - Quick reference for licensed maximum doses

100 - Clinical effectiveness

101 - Adverse effects

102 - Summary

103 - References

104 - Electroconvulsive therapy and psychosis

105 - Treatment refractory schizophrenia

106 - Adverse effects

107 - Summary

108 - References

109 - Omega 3 fatty acid (fish oils) in schizophren

11 - References

110 - Treatment

111 - Prevention

112 - Overall

113 - Summary recommendations fish oils (PUFAs)

114 - References

115 - Alternative routes of administration

116 - Inhaled

117 - Intranasal

118 - Intravenous

119 - Sublingual

12 - Equivalent doses

120 - Buccal

121 - Transdermal

122 - Rectal

123 - References

124 - Stopping antipsychotics

125 - Withdrawal effects of antipsychotics

126 - Neurobiology of withdrawal

127 - Pattern of tapering

128 - Tapering in practice

129 - When to attempt discontinuation

13 - References

130 - References

131 - ANTIPSYCHOTIC ADVERSE EFFECTS

132 - Extrapyramidal symptoms

133 - References

134 - Akathisia

135 - References

136 - Treatment of tardive dyskinesia

137 - Treatment first steps

138 - Treatment additional agents

139 - Treatment other possible options

14 - High dose antipsychotic medication prescribin

140 - References

141 - Antipsychotic induced weight gain

142 - Time course

143 - Doseresponse

144 - References

145 - Treatment of antipsychotic induced weight gai

146 - Monitoring

147 - Treatment and prevention

148 - References

149 - Neuroleptic malignant syndrome

15 - Efficacy

150 - References

151 - Catatonia

152 - References

153 - ECG changes QT prolongation

154 - Introduction

155 - QT prolongation

156 - Other ECG changes

157 - Quantifying risk

158 - Other risk factors

159 - ECG monitoring

16 - Adverse effects

160 - Metabolic inhibition

161 - Other cardiovascular risk factors

162 - Summary

163 - References